Andractim (Topical DHT): Research, Reported Dosing, and Safety Notes
Andractim is a topical dihydrotestosterone (DHT) cream, also indexed as topical DHT cream. This research profile collects four source types for Andractim (topical DHT) on one page: transcript dosing mentions, named-expert quotes, vendor report status, and PubMed-indexed literature. Every item links to its original source, so each claim can be checked against the video timestamp or PubMed record it came from. The page offers no medical guidance.
Andractim is a topical dihydrotestosterone (DHT) cream and a prescription medication in the United States. The Peptide Wiki profiles it from named-expert transcripts and PubMed-indexed literature, without medical guidance. The profile currently aggregates 8 PubMed-cited papers, 16 attributed expert mentions, and 9 transcript dosing protocols for Andractim (topical DHT), each linked to its original source.
- Also indexed as: topical DHT cream, Andractim.
- Dosing: 9 transcript-derived protocol mentions, each with a named speaker and a timestamp link (see table).
- Literature: 8 PubMed-indexed citations, each listed with PMID, and DOI where available (see list).
- Vendors: 0 vendor reports captured from named experts.
What is Andractim (topical DHT)?
Andractim is a topical dihydrotestosterone (DHT) cream, profiled on this page as a research compound. The profile draws on two source types: attributed transcript mentions from named creators, and PubMed-indexed literature connected to topical DHT. No disease-treatment claims are made here. Several mentions below discuss DHT in general or injectable DHT rather than the topical cream, so each quote carries its speaker, source video, and timestamp for context.
Named-source mentions: background and overview · 6 cited mentions
"Bullet Titan Biohacker and Ben Greenfield, they recommended starting a little bit lower... start low and then keep track of potential side effects like glucocorticoid receptor inhibition and then lowering cortisol levels and aromatase enzyme inhibition."
"Any updates on the DHT annotate? So I took it for one week and then I had to stop because what's the point of taking DHT when I'm not going to the gym and lifting hardcore. So I took 350 milligrams over the week. By Friday I looked pretty good."
"For TRT plus plus plus, what would be better and more sustainable, test and primo or mastrone or test and DHT? Yes, I don't have any experience with DHT yet. I did my blood work last Monday. I will start the DHT experiment uh next week Monday"
Show 3 more cited mentions on background and overview →
"That's why when you take exogenous DHT, which is what I'm doing now, in the long term you might have a compounding effect of testosterone converting into DHT because your 5-alpha-reductase enzymes are upregulated"
"Does Masteron really do anything that injectable DHT doesn't do? We don't know, but probably not."
"As soon as the DHT was hitting my system, it's like - I want to train, goddamn it."
Andractim (topical DHT) Dosing Protocols Reported in Transcripts
Named sources report DHT amounts ranging from about 1 mg every 3 days to 700 mg/week across 9 transcript mentions tracked here. Each row names the speaker and source video and links to the exact timestamp. Routes are recorded as each speaker described them, and some rows refer to injectable DHT rather than a topical cream. All 9 rows are anecdotal reports kept for research context only. This is not medical advice.
| Speaker | Source | Timestamp | Protocol reported | Evidence |
|---|---|---|---|---|
| Vigorous Steve | FULL Quad Tear Recovery Protocol, HGH Serum Tests, Maximize Cardio... | 00:22:46 | Vigorous Steve reports taking 350 mg over one week of what the transcript renders as "DHT annotate" (route recorded as topical/injectable). He notes aromatase and glucocorticoid inhibition and a water dump, and reports stopping due to impaired wound healing after surgery. | Anecdotal (transcript) |
| Vigorous Steve | Pool Party Protocols, 16-Week Tren Cycle, No GH Bloat, EQ Safety,... | 00:59:30 | Vigorous Steve reports a planned DHT experiment: 350 mg/week in May (4 weeks), then 700 mg/week in June (4 weeks). He also reports others using 50, 150, 175, and 225 mg/week, up to a 700 mg/week range. | Anecdotal (transcript) |
| Ryan Ballow | 300MG Test E + 300MG Mast = DIALED IN? Livestream HIGHLIGHTS | 00:07:39 | Ryan Ballow reports that a 100 mg DHT cream delivers about 25 mg per click, and that 200 mg/day topical roughly equates to about 15 to 20 mg/day cypionate equivalent. | Anecdotal (transcript) |
| Ryan Ballow | 200MG a week is BETTER, Dialing in LIBIDO, and TRT Biohacking DISCUSSION | 00:37:15 | Ryan Ballow reports, in the context of a natural athlete, an ultra-low dose of about 1 mg every 3 days applied transcrotally, which the speaker describes as uncharted territory. | Anecdotal (transcript) |
| Vigorous Steve | (Not Really) Enhanced Games REVIEW! Point Proven, Or Major Flop?... | 01:17:13 | Vigorous Steve reports a personal experiment, one week in before an injury: 300 mg testosterone plus 350 mg DHT per week. | Anecdotal (transcript) |
| Vigorous Steve | The ULTIMATE Hair Loss & Gyno Prevention Tier List (No Surgery Required) | 00:28:01 | Vigorous Steve reports starting what the speaker calls a modest 350 mg DHT injectable, against the advice of others, for PFS recovery. | Anecdotal (transcript) |
| Vigorous Steve | Low-Dose MENT Year-Round, Melt Love Handle Fat, Injectable YK-11,... | 01:45:39 | Vigorous Steve reports a plan of 350 mg in month 1, then 700 mg in month 2 if warranted, 4 weeks each. | Anecdotal (transcript) |
| Cortex Labs (Ryan Ballow) | Supercharging LIBIDO, Steele Rod Protocols, and TRT Biohacking LIVE Q&A | 00:38:41 | Ryan Ballow (Cortex Labs) reports that a 10% DHT gel (100 mg/mL) delivers about 5-6 mg per drop, and describes diluting it with MCT oil to about 1 mg per drop for finer control. | Anecdotal (transcript) |
| Cortex Labs (Ryan Ballow) | PFS Estrogen Windows, EQ but NO LIBIDO on TRT FIX, and PROP EOD = GOLD | 00:01:54 | Ryan Ballow (Cortex Labs) reports that a stock 20% DHT dropper delivers approximately 7-10 mg DHT per 2 minutes (full dropper). | Anecdotal (transcript) |
Vendor Reports for Andractim (topical DHT)
No vendor reports for Andractim (topical DHT) are tracked yet. See our vendor directory.
Andractim (topical DHT) Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
This page cites two safety-related mentions for Andractim (topical DHT). Both are anecdotal and shown with their original attribution and source link:
- Vigorous Steve reports that others recommended starting lower and tracking potential side effects such as glucocorticoid receptor inhibition, lowered cortisol levels, and aromatase enzyme inhibition. See quote · source @ 58:50.
- Vigorous Steve reports stopping a one-week, 350 mg run due to impaired wound healing after surgery. See dosing row 1 · source @ 22:46.
What Experts Say About Andractim (topical DHT)
This roster lists 2 experts from our source library who discuss Andractim (topical DHT), followed by 4 more expert mentions. Each entry shows the most context-rich mention, with a link to the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“Bullet Titan Biohacker and Ben Greenfield, they recommended starting a little bit lower... start low and then keep track of potential side effects like glucocorticoid receptor inhibition and then...”
-
“As soon as the DHT was hitting my system, it's like - I want to train, goddamn it.”
See 4 more expert mentions →
-
“Any updates on the DHT annotate? So I took it for one week and then I had to stop because what's the point of taking DHT when I'm not going to the gym and lifting hardcore. So I took 350...”
-
“For TRT plus plus plus, what would be better and more sustainable, test and primo or mastrone or test and DHT? Yes, I don't have any experience with DHT yet. I did my blood work last Monday. I...”
-
“That's why when you take exogenous DHT, which is what I'm doing now, in the long term you might have a compounding effect of testosterone converting into DHT because your 5-alpha-reductase enzymes...”
-
“Does Masteron really do anything that injectable DHT doesn't do? We don't know, but probably not.”
User Reviews
A user reviews aggregator (Reddit, YouTube comments, and Discord research notes) is planned for Q3 2026. Until then, see the expert quotes above and the PubMed citations below.
Research Efficacy Snapshot
None of the excerpts below are Andractim trial results. They come from PubMed-indexed papers and one named-source transcript linked to Andractim (topical DHT) in our research feed, and they cover saw palmetto oil (VISPO), topical and oral finasteride, and androgenetic alopecia (AGA) background. Read them as related literature. Each line quotes its source verbatim, links to the original record, and lists the PMID so it can be matched to the full citation list.
Saw palmetto oil in AGA (Sudeep H et al, 2023 · PMID 38021422)
Randomized, placebo-controlled study. Full record: citation 2.
- "This study aimed to assess the safety and efficacy of VISPOTM, a standardized saw palmetto oil (2-3% β-sitosterol), in subjects with mild-to-moderate AGA." · Sudeep H et al, 2023 PubMed
- "In a double-blind, placebo-controlled, four-arm clinical study, 80 healthy male and female subjects aged 18-50 years were randomly allocated (1:1:1:1) to receive either 400 mg capsules of VISPO or 5 mL of a topical formulation containing 20% VISPO or the respective placebo once daily for 16 weeks." · Sudeep H et al, 2023 PubMed
- "At the end of the study, oral and topical formulations of VISPO reduced hair fall by up to 29% (p<0.001) and 22.19% (p<0.01) from the baseline, respectively." · Sudeep H et al, 2023 PubMed
- "Hair density increased by 5.17% and 7.61% in the oral and topical VISPO groups, respectively (p<0.001)." · Sudeep H et al, 2023 PubMed
Topical vs oral finasteride (Gupta A et al, 2022 · PMID 35238144)
Review summarizing earlier finasteride trials. Full record: citation 4.
- Partial excerpt: "In a phase III, randomized, controlled trial, the efficacies of topical 0.25% w/w finasteride spray (1-4 sprays; 50-200 μl/day) and once-daily finasteride 1 mg oral tablet were similar when administered for 24 weeks (mean change from baseline, 20.2 vs." · Gupta A et al, 2022 PubMed
- "Additionally, a double-blind, randomized trial compared the efficacies of twice-daily finasteride 1% topical gel and once-daily finasteride 1 mg oral tablet for 6 months, and found similar results in both groups." · Gupta A et al, 2022 PubMed
- "In an open-label pharmacodynamic study, a 7-day treatment of twice-daily finasteride 0.25% topical solution and once-daily finasteride 1 mg oral tablet provided similar inhibition of plasma DHT." · Gupta A et al, 2022 PubMed
Topical finasteride spray trial and AGA background (Piraccini B et al · PMID 34634163, PMID 24566563)
Full records: citation 5 (phase III trial, 2022) and citation 8 (AGA overview, 2014).
- Partial excerpt: "55.6%), with topical vs." · Piraccini B et al, 2022 PubMed
- "Androgenetic alopecia (AGA) is the most common form of alopecia, affecting up to 80% of men and 50% of women in the course of their life." · Piraccini B et al, 2014 PubMed
Named-source transcript question
- "How many milligrams of DHT do the 20% gel you may contain in one dose?" · cohost on "PFS Estrogen Windows, EQ but NO LIBIDO on TRT FIX, and PROP " @ 1:22 The reported answer from the same video is recorded in dosing row 9.
Andractim (topical DHT) Research and Studies
Our research feed links 8 PubMed-indexed papers to Andractim (topical DHT), published between 2014 and 2025. By title, 7 of the 8 cover androgenetic alopecia, including topical finasteride and saw palmetto oil, and one covers micropenis. Treat them as related literature, not as Andractim-specific trials. Papers appear newest first, each with PMID, authors, journal, DOI where available, and a link to its PubMed record.
Andractim (topical DHT) Legal Status
Andractim (topical DHT) is a prescription medication in the United States, and this page presents it as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply, and prescription rules differ by country. Always verify current regulatory status. Last verified: 2026-07-05.
Frequently Asked Questions
What is Andractim (topical DHT)?
Andractim is a topical dihydrotestosterone (DHT) cream, profiled on this page as a research compound and listed as a prescription medication in the United States. See the What is Andractim section for attributed background mentions.
Is Andractim (topical DHT) FDA-approved?
This page does not state an FDA approval status. It notes that Andractim (topical DHT) is a prescription medication in the United States and presents it as a research compound. FDA approval status, scheduling, and state-specific rules may apply and can change, so verify current regulatory status before any decision. See Legal Status.
What dosing is reported for Andractim (topical DHT)?
Named sources report a wide range, and all 9 transcript mentions are anecdotal. For example, Vigorous Steve reports a 350 mg/week DHT experiment (row 2), and Ryan Ballow reports an ultra-low dose of about 1 mg every 3 days (row 4). Some rows refer to injectable DHT rather than a topical cream. Each mention links to its source timestamp in the Dosing Protocols table. None of this is medical advice.
What side effects are reported for Andractim (topical DHT)?
Two anecdotal safety mentions are cited on this page. Vigorous Steve reports others recommending tracking glucocorticoid receptor inhibition, lowered cortisol levels, and aromatase enzyme inhibition, and separately reports stopping a 350 mg run due to impaired wound healing after surgery. See Side Effects and Safety.
How much research has been published on Andractim (topical DHT)?
Our current research feed links 8 PubMed-indexed papers to Andractim (topical DHT). By title, they cover androgenetic alopecia and micropenis rather than Andractim-specific trials. See Research and Studies for the full citation list with PMIDs.
Are there vendor reports for Andractim (topical DHT)?
No vendor reports for Andractim (topical DHT) are tracked yet. See the Vendor Reports section.